Furthermore, treatment with etomoxir resulted in a significant decrease in the cell number (Vehicle: 277.4 ± 26.8 vs. Etomoxir: 76.7 ± 13.1, P < 0.001), size (Vehicle: 257.6 ± 57.2 μm vs. Etomoxir: 92.47 ± 15.3 μm, P < 0.01) and the number of nuclei per osteoclast (TRAP, Vehicle: 18.1 ± 2.0 vs. Etomoxir: 8.2 ± 1.1, P < 0.001; F-actin, Vehicle: 22.8 ± 2.7 vs. Etomoxir: 9.3 ± 1.9, P < 0.001) of mature osteoclasts, as well as and pit area of bone resorption lacunae in patients with RA (Vehicle: 437.2 ± 11.7 vs. Etomoxir: 142.13 ± 9.9, P < 0.001) (Figures 4M-R). This evidence concerns the gene ACP5 and rheumatoid arthritis.